Events

Investival Showcase Virtual w/ Jackie Hunter

External And Internal Convergence - A Cross-Sector Approach To Healthcare’s Biggest Challenges.

Wednesday, November 11 - 14:45 GMT

As health economies face challenges of improving outcomes while lowering cost, among many others, a cross-sector approach to health and care is vital. Alongside new biotechnologies and combination therapeutic approaches has come the rapid expansion of AI in multiple settings, new digital technologies and, importantly, the more tech-savvy and engaged patient, convergence is starting to make meaningful impacts. How is the industry developing new core digital capabilities, alliances, partnerships and innovative ways to drive better outcomes? 

  • In which ways are health and care industry leaders’ driving solutions to healthcare’s biggest challenges through different therapeutics, digital, and device combination approaches? 
  • To what extent and in which ways does external innovation fit into this picture for pharma companies like J&J? 
  • How can the wider industry work towards true and meaningful convergence to improve outcomes? 
  • How can this holistic approach and personalised medicine approaches go hand in hand? 

Panelists:

Melanie Senior, Writer and Analyst (moderator) 

Prabhu Velusami, Senior Director, New Ventures and Transactions, Johnson & Johnson 

Dan Vahdat, CEO, Huma 

Nikolaj Sorensen, CEO, Orexo 

Jackie Hunter, Board Director, BenevolentAI 

Eric Marcotulli, CEO, Elysium Health

Register →


Jackie Hunter
Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022